Structure Therapeutics Inc. (GPCR): R&D Expense

Annual figures by period end, from SEC filings.

$225.25M

Year ended 2025-12-31

$294.24M

Trailing 12 months to 2026-06-30

+83.9%

3-year compound annual growth

2022-12-31 R&D Expense (USD) 2025-12-31

Period ended	R&D Expense	Change YoY	Source filing
2025-12-31	$225.25M	+107.0%	2026-02-26, From 2025-01-01
2024-12-31	$108.81M	+55.2%	2026-02-26, From 2024-01-01
2023-12-31	$70.10M	+93.7%	2026-02-26, From 2023-01-01
2022-12-31	$36.19M	n/a	2024-03-08, From 2022-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	R&D Expense	Change YoY
Structure Therapeutics Inc. (GPCR)	2025-12-31	$225.25M	+107.0%
Acadia Pharmaceuticals Inc (ACAD)	2025-12-31	$328.80M	+8.4%
Ligand Pharmaceuticals Inc (LGND)	2025-12-31	$81.18M	+278.9%
Amphastar Pharmaceuticals, Inc. (AMPH)	2025-12-31	$85.84M	+16.1%
Innoviva, Inc. (INVA)	2025-12-31	$30.60M	+124.1%
Ultragenyx Pharmaceutical Inc. (RARE)	2025-12-31	$750.00M	+7.4%
Collegium Pharmaceutical, Inc (COLL)	2024-12-31	$0	n/a
Phibro Animal Health Corp (PAHC)	2026-06-30	$24.55M	+3.5%
Supernus Pharmaceuticals, Inc. (SUPN)	2025-12-31	$106.23M	-2.4%

Compare GPCR, ACAD, LGND, AMPH side by side · Screen every company in Pharmaceutical Preparations ↗